{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:44:10Z","timestamp":1785890650497,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-027"],"award-info":[{"award-number":["2021-I2M-1-027"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2017-I2M-1-010"],"award-info":[{"award-number":["2017-I2M-1-010"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703566"],"award-info":[{"award-number":["81703566"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jare.2026.06.032","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:33:20Z","timestamp":1782920000000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Melanoma cell-derived LAG-3 enhances CXCL1\/8-driven MDSCs recruitment and immune escape via TRIM28-mediated I\u03baB\u03b1 degradation"],"prefix":"10.1016","author":[{"given":"Nina","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.jare.2026.06.032_b0005","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0010","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jare.2026.06.032_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100639","article-title":"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"7","author":"Garralda","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.jare.2026.06.032_b0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"10.1016\/j.jare.2026.06.032_b0025","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2026.06.032_b0030","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.jare.2026.06.032_b0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","article-title":"LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation","volume":"23","author":"Guy","year":"2022","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.jare.2026.06.032_b0045","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4(+) T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.jare.2026.06.032_b0050","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"10.1016\/j.jare.2026.06.032_b0055","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"10.1016\/j.jare.2026.06.032_b0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jare.2026.06.032_b0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0070","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.jare.2026.06.032_b0075","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202301018R","article-title":"Advancement of anti-LAG-3 in cancer therapy","volume":"37","author":"Li","year":"2023","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.jare.2026.06.032_b0080","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0800185","article-title":"LAG-3 regulates plasmacytoid dendritic cell homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2026.06.032_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102962","article-title":"Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma","volume":"59","author":"Fr\u00f6hlich","year":"2020","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.jare.2026.06.032_b0090","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jare.2026.06.032_b0095","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jare.2026.06.032_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153990","article-title":"Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: an emerging target for immunotherapy","volume":"236","author":"Zhang","year":"2022","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000552","article-title":"LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma","volume":"8","author":"Kl\u00fcmper","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jare.2026.06.032_b0115","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","article-title":"Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)","volume":"22","author":"Alfaro","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.06.032_b0120","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1038\/ncomms5820","article-title":"Negative regulation of NF-\u03baB activity by brain-specific TRIpartite motif protein 9","volume":"5","author":"Shi","year":"2014","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jare.2026.06.032_b0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2413","article-title":"TRIM family proteins and their emerging roles in innate immunity","volume":"8","author":"Ozato","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.jare.2026.06.032_b0130","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.jare.2026.06.032_b0135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/jclinpath-2022-208254","article-title":"Development of a LAG-3 immunohistochemistry assay for melanoma","volume":"76","author":"Johnson","year":"2023","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.1016\/j.jare.2026.06.032_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23244","article-title":"Ectopic expression of LAG-3 in non-small-cell lung cancer cells and its clinical significance","volume":"34","author":"Ma","year":"2020","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"10.1016\/j.jare.2026.06.032_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.jare.2026.06.032_b0150","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1002\/ctm2.365","article-title":"LAG3 and its emerging role in cancer immunotherapy","volume":"11","author":"Wang","year":"2021","journal-title":"Clin Transl Med"},{"issue":"2","key":"10.1016\/j.jare.2026.06.032_b0155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2326-6066.CIR-20-0312","article-title":"Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity","volume":"9","author":"Yang","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"10.1016\/j.jare.2026.06.032_b0160","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1158\/0008-5472.CAN-11-0156","article-title":"IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells","volume":"71","author":"Fernando","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jare.2026.06.032_b0165","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"10.1016\/j.jare.2026.06.032_b0170","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1074\/jbc.RA119.007455","article-title":"Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation","volume":"294","author":"Maeda","year":"2019","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.jare.2026.06.032_b0180","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2015.02.009","article-title":"Loss of somatostatin receptor subtype 2 promotes growth of KRAS-induced pancreatic tumors in mice by activating PI3K signaling and overexpression of CXCL16","volume":"148","author":"Chalabi-Dchar","year":"2015","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.jare.2026.06.032_b0185","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nri2423","article-title":"New regulators of NF-kappaB in inflammation","volume":"8","author":"Ghosh","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.jare.2026.06.032_b0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.06.032_b0195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","article-title":"Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity","volume":"18","author":"Karin","year":"2000","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0200","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","article-title":"TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance","volume":"8","author":"Ma","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.jare.2026.06.032_b0205","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/s41418-020-00701-y","article-title":"Sequential ubiquitination of p53 by TRIM28, RLIM, and MDM2 in lung tumorigenesis","volume":"28","author":"Jin","year":"2021","journal-title":"Cell Death Differ"},{"issue":"13","key":"10.1016\/j.jare.2026.06.032_b0210","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0215","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2261248","article-title":"Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies","volume":"12","author":"Gide","year":"2023","journal-title":"Oncoimmunology"},{"issue":"15","key":"10.1016\/j.jare.2026.06.032_b0220","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jare.2026.06.032_b0225","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.jare.2026.06.032_b0230","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"issue":"26","key":"10.1016\/j.jare.2026.06.032_b0235","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1200\/JCO-25-00494","article-title":"Long-term survival and biomarker analysis evaluating neoadjuvant plus adjuvant relatlimab (anti-LAG3) and nivolumab (anti-PD1) in patients with resectable melanoma","volume":"43","author":"Burton","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.06.032_b0240","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2017","article-title":"Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM","volume":"37","author":"Lim","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0245","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.032_b0250","first-page":"62","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.jare.2026.06.032_b0255","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jare.2026.06.032_b0260","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226005163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226005163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:44:37Z","timestamp":1785887077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123226005163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"alternative-id":["S2090123226005163"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.06.032","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melanoma cell-derived LAG-3 enhances CXCL1\/8-driven MDSCs recruitment and immune escape via TRIM28-mediated I\u03baB\u03b1 degradation","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}